S&P 500   2,709.34 (+1.88%)
DOW   23,084.44 (+1.90%)
QQQ   199.08 (+1.36%)
AAPL   264.90 (+2.11%)
FB   170.45 (+0.96%)
MSFT   164.83 (+0.82%)
GOOGL   1,197.68 (+1.28%)
AMZN   2,019.55 (+0.40%)
CGC   14.89 (+2.69%)
NVDA   264.43 (+2.08%)
MU   48.18 (+3.50%)
TSLA   548.65 (+0.59%)
AMD   48.16 (+1.26%)
T   29.39 (-2.29%)
ACB   0.83 (+3.75%)
F   4.95 (+5.10%)
NFLX   372.79 (+0.14%)
BAC   22.96 (+3.70%)
GILD   74.03 (-0.86%)
DIS   101.12 (-0.43%)
S&P 500   2,709.34 (+1.88%)
DOW   23,084.44 (+1.90%)
QQQ   199.08 (+1.36%)
AAPL   264.90 (+2.11%)
FB   170.45 (+0.96%)
MSFT   164.83 (+0.82%)
GOOGL   1,197.68 (+1.28%)
AMZN   2,019.55 (+0.40%)
CGC   14.89 (+2.69%)
NVDA   264.43 (+2.08%)
MU   48.18 (+3.50%)
TSLA   548.65 (+0.59%)
AMD   48.16 (+1.26%)
T   29.39 (-2.29%)
ACB   0.83 (+3.75%)
F   4.95 (+5.10%)
NFLX   372.79 (+0.14%)
BAC   22.96 (+3.70%)
GILD   74.03 (-0.86%)
DIS   101.12 (-0.43%)
S&P 500   2,709.34 (+1.88%)
DOW   23,084.44 (+1.90%)
QQQ   199.08 (+1.36%)
AAPL   264.90 (+2.11%)
FB   170.45 (+0.96%)
MSFT   164.83 (+0.82%)
GOOGL   1,197.68 (+1.28%)
AMZN   2,019.55 (+0.40%)
CGC   14.89 (+2.69%)
NVDA   264.43 (+2.08%)
MU   48.18 (+3.50%)
TSLA   548.65 (+0.59%)
AMD   48.16 (+1.26%)
T   29.39 (-2.29%)
ACB   0.83 (+3.75%)
F   4.95 (+5.10%)
NFLX   372.79 (+0.14%)
BAC   22.96 (+3.70%)
GILD   74.03 (-0.86%)
DIS   101.12 (-0.43%)
S&P 500   2,709.34 (+1.88%)
DOW   23,084.44 (+1.90%)
QQQ   199.08 (+1.36%)
AAPL   264.90 (+2.11%)
FB   170.45 (+0.96%)
MSFT   164.83 (+0.82%)
GOOGL   1,197.68 (+1.28%)
AMZN   2,019.55 (+0.40%)
CGC   14.89 (+2.69%)
NVDA   264.43 (+2.08%)
MU   48.18 (+3.50%)
TSLA   548.65 (+0.59%)
AMD   48.16 (+1.26%)
T   29.39 (-2.29%)
ACB   0.83 (+3.75%)
F   4.95 (+5.10%)
NFLX   372.79 (+0.14%)
BAC   22.96 (+3.70%)
GILD   74.03 (-0.86%)
DIS   101.12 (-0.43%)
Log in

NASDAQ:BIOCBiocept Stock Price, Forecast & News

$0.28
0.00 (-0.18 %)
(As of 04/8/2020 11:24 AM ET)
Add
Compare
Today's Range
$0.27
Now: $0.28
$0.28
50-Day Range
$0.24
MA: $0.36
$0.78
52-Week Range
$0.21
Now: $0.28
$2.11
Volume59,771 shs
Average Volume13.55 million shs
Market Capitalization$30.27 million
P/E RatioN/A
Dividend YieldN/A
Beta0.08
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Read More
Biocept logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.53 million
Book Value$0.24 per share

Profitability

Net Income$-25,140,000.00
Net Margins-455.14%

Miscellaneous

Employees95
Market Cap$30.27 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter.


Biocept (NASDAQ:BIOC) Frequently Asked Questions

How has Biocept's stock been impacted by COVID-19 (Coronavirus)?

Biocept's stock was trading at $0.3769 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOC stock has decreased by 26.1% and is now trading at $0.2785. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biocept?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biocept.

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Biocept.

How were Biocept's earnings last quarter?

Biocept Inc (NASDAQ:BIOC) posted its earnings results on Wednesday, March, 25th. The medical research company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.10. The medical research company had revenue of $1.78 million for the quarter. Biocept had a negative net margin of 455.14% and a negative return on equity of 218.69%. View Biocept's earnings history.

What price target have analysts set for BIOC?

1 Wall Street analysts have issued 1 year target prices for Biocept's shares. Their forecasts range from $1.00 to $1.00. On average, they expect Biocept's share price to reach $1.00 in the next year. This suggests a possible upside of 259.1% from the stock's current price. View analysts' price targets for Biocept.

Has Biocept been receiving favorable news coverage?

News stories about BIOC stock have trended very negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biocept earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutBiocept.

Who are some of Biocept's key competitors?

What other stocks do shareholders of Biocept own?

Who are Biocept's key executives?

Biocept's management team includes the following people:
  • Mr. Michael W. Nall, CEO, Pres & Director (Age 56)
  • Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)
  • Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)
  • Dr. Soon Kap Hahn Ph.D., Founder
  • Mr. Pavel Tsinberg, Director of Technology Devel.

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.28.

How big of a company is Biocept?

Biocept has a market capitalization of $30.27 million and generates $5.53 million in revenue each year. Biocept employs 95 workers across the globe. View additional information about Biocept.

What is Biocept's official website?

The official website for Biocept is http://www.biocept.com/.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: What is the LIBOR?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel